Michael Johnson, MD
Family Medicine · Hastings, NENPI 1760426852
Payments from drug & device makers
Across 162 payments — averaging $15.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$890
- GSK$213
- Amgen$164
- Novo Nordisk$152
- Otsuka America Pharmaceutical, Inc.$143
- Lilly USA, LLC$78
- plus $834 from 26 others
What the payments were for
- Food & beverage$2,475100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 59 | $890 |
| GSK | 22 | $213 |
| Amgen | 12 | $164 |
| Novo Nordisk | 10 | $152 |
| Otsuka America Pharmaceutical, Inc. | 7 | $143 |
| Lilly USA, LLC | 6 | $78 |
| Bayer | 5 | $68 |
| Pfizer | 4 | $63 |
| Zimmer Biomet | 1 | $59 |
| Johnson & Johnson | 3 | $54 |
| Paragon 28, Inc. | 1 | $47 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $46 |
| Boehringer Ingelheim | 3 | $46 |
| Novartis | 3 | $45 |
| Astellas Pharma US Inc | 2 | $36 |
| Abiomed | 1 | $35 |
| Merck | 2 | $34 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $31 |
| Nestle Healthcare Nutrition Inc. | 2 | $29 |
| Kowa Pharmaceuticals America, Inc. | 2 | $25 |
| Arbor Pharmaceuticals, Inc. | 1 | $24 |
| Sanofi-aventis U.S. LLC | 2 | $24 |
| Gilead | 1 | $24 |
| Organon | 1 | $22 |
| Teva Pharmaceuticals USA, Inc. | 1 | $18 |
| Exact Sciences | 1 | $17 |
| Bausch Health US, LLC | 1 | $16 |
| Xeris Pharmaceuticals, Inc. | 1 | $16 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $15 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $14 |
| Alkermes, Inc. | 1 | $13 |
| Dexcom, Inc. | 1 | $11 |
How this compares
$2,475 in reported general payments places this provider in the 75th percentile of 981 family medicine providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 87 | $91,836 |
| EliquisApixaban | 79 | $76,287 |
| TrulicityDulaglutide | 78 | $65,881 |
| OzempicSemaglutide | 56 | $58,724 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 77 | $55,186 |
| XareltoRivaroxaban | 63 | $42,949 |
| VraylarCariprazine Hcl | 11 | $18,433 |
| MyrbetriqMirabegron | 22 | $17,034 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 73 | $15,029 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 29 | $14,570 |
| FarxigaDapagliflozin Propanediol | 12 | $13,180 |
| Breo ElliptaFluticasone/Vilanterol | 30 | $12,917 |
| MounjaroTirzepatide | 11 | $11,840 |
| Bydureon BciseExenatide Microspheres | 13 | $11,415 |
| TradjentaLinagliptin | 12 | $9,592 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Shingrix, Anoro Ellipta, Breo Ellipta, Incruse Ellipta | $213 | $101,948221 claims |
| Boehringer IngelheimJardiance, Tradjenta | $46 | $101,42999 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $78 | $77,72189 claims |
| PfizerEliquis | $63 | $76,28779 claims |
| Novo NordiskOzempic | $152 | $58,72456 claims |
| Johnson & JohnsonXarelto | $54 | $42,94963 claims |
| AbbVieVraylar | $890 | $18,43311 claims |
| Astellas Pharma US IncMyrbetriq | $36 | $17,03422 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 981 family medicine providers in Nebraska.
Other family medicine in Hastings
- Timothy ZimmermanHastings$41K
- Brandon EssinkCreighton$92.8M
- Adam BroszGrand Island$60M
- David EnszSouth Sioux City$33.3M
- Allen HuntLincoln$17.2M
- Thomas WolfFremont$8.2M
- William FitzgibbonsElkhorn$7M
- Kenneth BladOmaha$1.6M
- Lorrie McGillPapillion$1.5M
- Ralph HaukeOmaha$657K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.